Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Clustered metabolic abnormalities blunt regression of hypertensive left ventricular hypertrophy: the LIFE study
Nutrition, Metabolism and Cardiovascular Diseases, Volume 19, No. 9, Year 2009
Notification
URL copied to clipboard!
Description
Background and aims: Clusters of metabolic abnormalities resembling phenotypes of metabolic syndrome predicted outcome in the LIFE study, independently of single risk markers, including obesity, diabetes and baseline ECG left ventricular hypertrophy (LVH). We examined whether clusters of two or more metabolic abnormalities (MetAb, including obesity, high plasma glucose without diabetes, low HDL-cholesterol) in addition to hypertension were associated to levels of ECG LVH reduction comparable to that obtained in hypertensive subjects without or with only one additional metabolic abnormality (no-MetAb). Methods and results: We studied 5558 non-diabetic participants without MetAb (2920 women) and 1235 with MetAb (751 women) from the LIFE-study cohort. MetAb was defined by reported LIFE criteria, using partition values from the ATPIII recommendations. Time-trends of Cornell voltage-duration product (CP) over 5 years was assessed using a quadratic polynomial contrast, adjusting for age, sex, prevalent cardiovascular disease and treatment arm (losartan or atenolol). At baseline, despite similar blood pressures, CP was greater in the presence than in the absence of MetAb (p < 0.0001). During follow-up, despite similar reduction of blood pressure, CP decreased less in patients with than in those without MetAb, even after adjustment for the respective baseline values (both p < 0.002). Losartan was more effective than atenolol in reducing CP independently of MetAb. Conclusions: Clusters of metabolic abnormalities resembling phenotypes of metabolic syndrome are related to greater initial ECG LVH in hypertensive patients with value of blood pressure similar to individuals without metabolic abnormalities, and are associated with less reduction of ECG LVH during antihypertensive therapy, potentially contributing to the reported adverse prognosis of metabolic syndrome. © 2009 Elsevier B.V. All rights reserved.
Authors & Co-Authors
de Simone, Giovanni
Italy, Naples
Università Degli Studi Di Napoli Federico Ii
United States, New York
Weill Cornell Medicine
Okin, Peter M.
United States, New York
Weill Cornell Medicine
Gerdts, Eva
Norway, Bergen
Haukeland Universitetssjukehus
Olsen, Michael Hecht
Denmark, Glostrup
Amtssygehuset I Glostrup
Wachtell, Kristian
Denmark, Glostrup
Amtssygehuset I Glostrup
Hille, Darcy A.
United States, Rahway
Merck & Co., Inc.
Dahlof̈, Björn L.
Sweden, Gothenburg
Sahlgrenska Universitetssjukhuset
Kjeldsen, Sverre Erik
Norway, Oslo
Ulleval University Hospital
Devereux, Richard Blyton
United States, New York
Weill Cornell Medicine
Statistics
Citations: 28
Authors: 9
Affiliations: 7
Identifiers
Doi:
10.1016/j.numecd.2008.12.012
ISSN:
09394753
Research Areas
Noncommunicable Diseases
Study Design
Cohort Study
Participants Gender
Female